What to Expect at the American Heart Association 2019 Scientific Sessions

PRESIDENTIAL SESSION – Tuesday, 12:45 pm
This year’s presidential session, with remarks by American Heart Association CEO Nancy Brown, will also feature select song performances by theater stars from the Broadway hit Hamilton. The Conner Presidential Address will be given by distinguished cardiologist Robert A. Harrington, and the Keynote Address will be delivered by Murat Sonmez of the World Economic Forum.

View Presidential Sessions

As in previous years, there will be plenty of interesting late-breaking clinical science this at this year’s meeting, including novel approaches to cardiovascular disease risk reduction, updates on interventional management for patients with acute coronary syndromes, and much more. See the LBCT lineup below.

View Late Breaking Clinical Trial Sessions


LBCT I – Saturday Morning

Outside the Box: New Approaches to Cardiovascular Disease Risk Reduction

  • The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
  • Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol – Results From the Phase 3 ORION-10 Trial
  • The COLchicine Cardiovascular Outcomes Trial (COLCOT)
  • Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes – Results of the BETonMACE Trial


LBCT II – Saturday Afternoon

Results for the Ischemia Trials: To Intervene or Not to Intervene

  • International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes
  • International Study of Comparative Health Effectiveness With Medical and Invasive Approaches- Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes


LBCT III – Saturday Evening

Controversies in Contemporary Management of Aortic Stenosis

  • Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results
  • Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves (GALILEO-4D)
  • Balloon-Expandable versus Self-Expandable TAVR on Paravalvular Regurgitation and 2-Year Mortality: A Propensity-Matched Comparison From the FRANCE-TAVI Registry
  • Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis


LBCT IV – Sunday Morning (Early Session)

State of the Art Interventional Management for Acute Coronary Syndrome Patients

  • Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention for Acute Coronary Syndrome
  • Colchicine in Percutaneous Coronary Intervention
  • Culprit Lesion Plaque Morphology in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography (OCT) Substudy
  • One Year Outcomes of Coronary Angiography After Cardiac Arrest
  • Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella® vs Intra-Aortic Balloon Pump
  • The Comparative Effectiveness and Costs of Impella vs. Intra-Aortic Balloon Pump in the United States


LBCT V – Sunday Morning (Late Session)

Challenges in Heart Failure Management

  • Results From the Pediatric Heart Network’s Fontan Udenafil Exercise Longitudinal Trial
  • Effect of Treatment According to Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
  • Effect of Treatment on the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
  • Effects of Sacubitril/Valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction
  • Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure


LBCT VI – Monday Morning

New Frontiers in Lipid Therapy

  • Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy (EVAPORATE Study)
  • Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia – Results From the Phase 3 ORION-9 Trial
  • RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides
  • RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects
  • Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After an Ischemic Stroke of Atherosclerotic Origin, the Treat Stroke to Target Trial Results


In addition to the LBCTs, AHA 2019 also provides numerous opportunities to keep up with other important, impactful science. Take advantage of the gathering of diverse professionals and check out sessions addressing areas such as electrophysiology, population science, chronic management of acute coronary syndromes and coronary artery disease, heart failure therapies, and much more.

View Featured Science Sessions

Multiple opportunities for attendees to take a peek at the latest cutting-edge cardio technologies for many different scenarios. Topics include overcoming barriers to type 2 diabetes management, siRNA and gene sli

View Health Tech Sessions

Fellows can meet and greet, and swap notes and contacts, and get their professional networks started at these specially focused events held just for fellows in training.

View Fit Events

For those just starting out in the practice of cardiology, whether it’s in private practice or in hospital employ, there’s something for everyone at this session targeted towards early career professionals.

View Early Career Sessions